pd 173074 has been researched along with Multiple Myeloma in 5 studies
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To define the FGFR3 network in multiple myeloma, mass spectrometry was used to identify and quantify phosphotyrosine (pY) sites modulated by FGFR3 activation and inhibition in myeloma-derived KMS11 cells." | 5.35 | Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. ( Dharsee, M; Ewing, RM; Jin, LL; Li, Z; Moran, MF; Nikolic, A; St-Germain, JR; Stewart, II; Taylor, P; Tong, J; Trudel, S, 2009) |
| "To define the FGFR3 network in multiple myeloma, mass spectrometry was used to identify and quantify phosphotyrosine (pY) sites modulated by FGFR3 activation and inhibition in myeloma-derived KMS11 cells." | 1.35 | Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. ( Dharsee, M; Ewing, RM; Jin, LL; Li, Z; Moran, MF; Nikolic, A; St-Germain, JR; Stewart, II; Taylor, P; Tong, J; Trudel, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| St-Germain, JR | 1 |
| Taylor, P | 1 |
| Tong, J | 1 |
| Jin, LL | 1 |
| Nikolic, A | 1 |
| Stewart, II | 1 |
| Ewing, RM | 1 |
| Dharsee, M | 1 |
| Li, Z | 1 |
| Trudel, S | 2 |
| Moran, MF | 1 |
| de Brito, LR | 1 |
| Batey, MA | 1 |
| Zhao, Y | 1 |
| Squires, MS | 1 |
| Maitland, H | 1 |
| Leung, HY | 1 |
| Hall, AG | 1 |
| Jackson, G | 1 |
| Newell, DR | 1 |
| Irving, JA | 1 |
| Chell, V | 1 |
| Balmanno, K | 1 |
| Little, AS | 1 |
| Wilson, M | 1 |
| Andrews, S | 1 |
| Blockley, L | 1 |
| Hampson, M | 1 |
| Gavine, PR | 1 |
| Cook, SJ | 1 |
| Ely, S | 1 |
| Farooqi, Y | 1 |
| Affer, M | 1 |
| Robbiani, DF | 1 |
| Chesi, M | 1 |
| Bergsagel, PL | 1 |
| Grand, EK | 1 |
| Chase, AJ | 1 |
| Heath, C | 1 |
| Rahemtulla, A | 1 |
| Cross, NC | 1 |
5 other studies available for pd 173074 and Multiple Myeloma
| Article | Year |
|---|---|
Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.
Topics: Amino Acid Sequence; Cell Line, Tumor; Fibroblast Growth Factor 3; Humans; Ligands; Mass Spectrometr | 2009 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mic | 2011 |
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fe | 2013 |
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.
Topics: Animals; Apoptosis; Cell Differentiation; Cell Line, Tumor; Chromosomes, Human, Pair 14; Chromosomes | 2004 |
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
Topics: Cell Line, Tumor; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Humans; Multiple Myeloma; | 2004 |